WO2000059447A3 - Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables - Google Patents

Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables Download PDF

Info

Publication number
WO2000059447A3
WO2000059447A3 PCT/FR2000/000790 FR0000790W WO0059447A3 WO 2000059447 A3 WO2000059447 A3 WO 2000059447A3 FR 0000790 W FR0000790 W FR 0000790W WO 0059447 A3 WO0059447 A3 WO 0059447A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
useful
uterine bleeding
treatment
sex hormones
Prior art date
Application number
PCT/FR2000/000790
Other languages
English (en)
Other versions
WO2000059447A2 (fr
Inventor
Yannis Tsouderos
Original Assignee
Adir
Yannis Tsouderos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002361885A priority Critical patent/CA2361885A1/fr
Priority to PL00356767A priority patent/PL356767A1/xx
Priority to JP2000609012A priority patent/JP2002541076A/ja
Priority to AU36623/00A priority patent/AU3662300A/en
Priority to EA200100801A priority patent/EA200100801A1/ru
Priority to BR0008577-4A priority patent/BR0008577A/pt
Application filed by Adir, Yannis Tsouderos filed Critical Adir
Priority to KR1020017011124A priority patent/KR20010102464A/ko
Priority to EP00915247A priority patent/EP1143978A2/fr
Publication of WO2000059447A2 publication Critical patent/WO2000059447A2/fr
Publication of WO2000059447A3 publication Critical patent/WO2000059447A3/fr
Priority to NO20014022A priority patent/NO20014022D0/no
Priority to HK02106208.3A priority patent/HK1044486A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'une hormone sexuelle (en particulier l'estradiol seul ou avec la noréthisterone en combinaison avec une cyclodextrine méthylée) pour l'obtention d'une composition pharmaceutique convenant pour l'administration par voie nasale pour traiter les phénomènes de saignements utérins indésirables chez la femme.
PCT/FR2000/000790 1999-03-31 2000-03-30 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables WO2000059447A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL00356767A PL356767A1 (en) 1999-03-31 2000-03-30 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
JP2000609012A JP2002541076A (ja) 1999-03-31 2000-03-30 望ましくない子宮出血の処置に有用な鼻腔用医薬組成物を得るための性ホルモンの使用
AU36623/00A AU3662300A (en) 1999-03-31 2000-03-30 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
EA200100801A EA200100801A1 (ru) 1999-03-31 2000-03-30 Применение половых гормонов при изготовлении фармацевтической композиции для назального введения, предназначенной для лечения нежелательного маточного кровотечения
BR0008577-4A BR0008577A (pt) 1999-03-31 2000-03-30 Utilização de hormÈnios sexuais para a obtenção de uma composição farmacêutica nasal útil para o tratamento dos sangramentos uterinos indesejáveis
CA002361885A CA2361885A1 (fr) 1999-03-31 2000-03-30 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
KR1020017011124A KR20010102464A (ko) 1999-03-31 2000-03-30 바람직하지 않은 자궁 출혈을 치료하는데 유용한 비약제조성물을 수득하기 위한 성호르몬의 용도
EP00915247A EP1143978A2 (fr) 1999-03-31 2000-03-30 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
NO20014022A NO20014022D0 (no) 1999-03-31 2001-08-17 Anvendelse av kjonnshormoner for a oppna en nasal farmasoytisk sammensetning som er nyttig i behandlingen av uonsketlivmorblodning
HK02106208.3A HK1044486A1 (zh) 1999-03-31 2002-08-23 使用性激素來獲得可用於治療不合需要的子宮出血的鼻腔藥物組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/04022 1999-03-31
FR9904022A FR2791572A1 (fr) 1999-03-31 1999-03-31 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables

Publications (2)

Publication Number Publication Date
WO2000059447A2 WO2000059447A2 (fr) 2000-10-12
WO2000059447A3 true WO2000059447A3 (fr) 2001-04-26

Family

ID=9543854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/000790 WO2000059447A2 (fr) 1999-03-31 2000-03-30 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables

Country Status (16)

Country Link
EP (1) EP1143978A2 (fr)
JP (1) JP2002541076A (fr)
KR (1) KR20010102464A (fr)
CN (1) CN1346273A (fr)
AU (1) AU3662300A (fr)
BR (1) BR0008577A (fr)
CA (1) CA2361885A1 (fr)
EA (1) EA200100801A1 (fr)
FR (1) FR2791572A1 (fr)
HK (1) HK1044486A1 (fr)
HU (1) HUP0200244A3 (fr)
NO (1) NO20014022D0 (fr)
NZ (1) NZ513672A (fr)
PL (1) PL356767A1 (fr)
WO (1) WO2000059447A2 (fr)
ZA (1) ZA200106689B (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
EP0349091A1 (fr) * 1988-07-01 1990-01-03 Walter Adrianus Josephus Johannes Hermens Composition pharmaceutique
WO1997046574A1 (fr) * 1996-06-07 1997-12-11 Pherin Corporation Steroïdes de 19-nor-cholane utiles comme initiateurs neurochimiques d'une modification de la fonction hypothalamique humaine
WO1998003207A1 (fr) * 1996-07-23 1998-01-29 Pherin Pharmaceuticals, Inc. Steroides utilises en qualite de stimulateurs neurochimiques de l'organe vomero-nasal et permettant de soulager les symptomes premenstruel et de l'anxiete

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
EP0349091A1 (fr) * 1988-07-01 1990-01-03 Walter Adrianus Josephus Johannes Hermens Composition pharmaceutique
WO1997046574A1 (fr) * 1996-06-07 1997-12-11 Pherin Corporation Steroïdes de 19-nor-cholane utiles comme initiateurs neurochimiques d'une modification de la fonction hypothalamique humaine
WO1998003207A1 (fr) * 1996-07-23 1998-01-29 Pherin Pharmaceuticals, Inc. Steroides utilises en qualite de stimulateurs neurochimiques de l'organe vomero-nasal et permettant de soulager les symptomes premenstruel et de l'anxiete

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAYER S.R. ET AL: "Clinical manifestations and treatment of dysfunctional uterine bleeding.", JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, (1993) 269/14 (1823-1828)., XP000856624 *
BRENNER, PAUL F. ET AL: "Ovulation inhibition with nafarelin acetate nasal administration for six months", CONTRACEPTION (1985), 32(6), 531-51, XP000856801 *
BRUN J.L.: "[Management of uterine bleeding in 1994]. LE POINT SUR LE TRAITEMENT DES MENOMETRORRAGIES EN 1994.", CONTRACEPTION FERTILITE SEXUALITE, (1994) 22/3 (147-151)., XP000856625 *
COLL CAPDEVILA C: "Dysfunctional uterine bleeding and dysmenorrhea.", EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, (1997 DEC) 2 (4) 229-37. REF: 28, XP000856691 *
KARTHAUS M. ET AL: "Acute abdomen due to endometriosis as a diagnostic and therapeutic challenge in the treatment of acute myelocytic leukemia.", ANNALS OF HEMATOLOGY, (1997) 74/1 (29-31)., XP000856615 *
NILLIUS S.J.: "LH-RH nasal spray in contraception Future Aspects in Contraception. International Symposium. Heidelberg 5-8 September 1984.", CONTRACEPT. DELIV. SYST., (1984) 5/3 (36)., XP000856854 *

Also Published As

Publication number Publication date
AU3662300A (en) 2000-10-23
CA2361885A1 (fr) 2000-10-12
HK1044486A1 (zh) 2002-10-25
NO20014022L (no) 2001-08-17
HUP0200244A3 (en) 2003-05-28
WO2000059447A2 (fr) 2000-10-12
JP2002541076A (ja) 2002-12-03
NO20014022D0 (no) 2001-08-17
FR2791572A1 (fr) 2000-10-06
ZA200106689B (en) 2002-11-14
NZ513672A (en) 2001-09-28
BR0008577A (pt) 2002-10-01
CN1346273A (zh) 2002-04-24
EP1143978A2 (fr) 2001-10-17
PL356767A1 (en) 2004-07-12
KR20010102464A (ko) 2001-11-15
HUP0200244A2 (hu) 2002-07-29
EA200100801A1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
HUP0302093A3 (en) Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy
NZ516502A (en) Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
DK0836506T3 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
EP1319404A3 (fr) Composition pour traiter, ou pour la prévention des tumeurs du sein
PT748190E (pt) Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos
EP1249238A3 (fr) Composition pharmaceutique topique comprenant du béthanéchol
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
WO2002074292A3 (fr) Therapie de remplacement d'hormones
EA200900451A1 (ru) Способ получения композиции эстрадиола с медленным высвобождением ( варианты ), микросферы эстрадиола и холестерина и способ для одновременной контрацепции и гормонозамещения
MXPA04005211A (es) Sistemas terapeuticos transdermicos que contienen hormona esteroides y monocaprilato de propilenglicol.
WO2001074839A3 (fr) Procedes de preparation et d'utilisation de7$g(a),11?-dimethyl-17?-hydroxy-4-estren-3-one 17?-$i(trans)-4-$i(n)-butylcyclohexane carboxylate et 7$g(a),11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate
WO2001076638A3 (fr) Composition pour administration de medicament
AP1625A (en) Hormonal composition based on a progesterone and an oestrogen and use thereof.
RU2003107072A (ru) Применение гормональной композиции, содержащей сочетание эстрогена и прогестагена
GB0010683D0 (en) Cancer therapy
WO2000059447A3 (fr) Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
BRPI0417530A (pt) liberação transdérmica de hormÈnios sem a necessidade de melhoradores de penetração
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
LT2002035A (lt) Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas
HUP0202429A2 (en) Use of mesoprogestins (progesterone receptor modulators) for the preparation of pharmaceutical compositions for the treatment and prevention of benign hormone dependent gynecological disorders
WO2003084521A3 (fr) Traitement hormonal substitutif
RU1789216C (ru) Состав, обладающий контрацептивным действием

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804471.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN HU JP KR MX NO NZ PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN HU JP KR MX NO NZ PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000915247

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 36623/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001/06689

Country of ref document: ZA

Ref document number: 200106689

Country of ref document: ZA

Ref document number: 09913438

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 513672

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200100801

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2361885

Country of ref document: CA

Ref document number: 2361885

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 609012

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/008772

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017011124

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000915247

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017011124

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000915247

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017011124

Country of ref document: KR